mg ↔ units

Melanotan-2 mg to units converter

Set your Melanotan-2 vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

Last updated: May 6, 2026

Vial (mg)

Diluent (mL)

Dose (mg)

0.500

units

10.0

0.100

Concentration: 5.00 mg/mL (assumes a U-100 insulin syringe).

Melanotan 2 is a peptide people inject to develop a deeper tan with less sun exposure by activating the body's own pigment-producing cells. It binds to melanocortin receptors that signal melanocytes to make more melanin, and it can also trigger libido effects as a side effect. In small studies, users developed visibly darker skin within 2–4 weeks of consistent low-dose use. This page covers reconstitution math and how people typically log a loading-then-maintenance schedule.

How the Melanotan-2 mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the Melanotan-2 concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 5 mg/mL Melanotan-2 solution, 0.5 mg comes out to 10 units, and 10 units comes out to 0.5 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 10 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for Melanotan-2

Melanotan-2 is a synthetic analog of alpha-melanocyte-stimulating hormone. It is supplied in lyophilized vials commonly rated at 10 mg in the research market and is typically logged on a daily cadence during loading phases and less frequently during maintenance phases.

Melanotan-2 is a synthetic peptide analog of the body's native alpha-melanocyte-stimulating hormone (α-MSH). Its development originated from research conducted at the University of Arizona in the 1980s by a team of scientists including Mac E. Hadley and Victor J. Hruby. The primary research goal was to design a molecule that mimicked the function of α-MSH but possessed significantly greater stability and potency. The native α-MSH is a linear peptide that is subject to rapid enzymatic degradation in the body, giving it a very short biological half-life of only a few minutes. This inherent instability made it impractical for studies where sustained melanocortin receptor activation was desired, prompting the development of more durable analogs.

The key structural innovation of Melanotan-2 is its cyclization, which distinguishes it from the linear α-MSH. It is a small cyclic heptapeptide with the amino acid sequence cyclo[Asp-His-D-Phe-Arg-Trp-Lys]. This circular structure is formed by a lactam bridge between the aspartic acid and lysine residues. This modification makes the peptide conformationally constrained and far more resistant to the peptidases that would normally cleave the linear peptide chain. The result is a molecule with a dramatically extended biological half-life, allowing for a much longer duration of action after administration and enabling studies on the effects of sustained melanocortin system activation.

Melanotan-2 mechanism in plain English

Melanotan-2 binds to multiple melanocortin receptors. Personal logs pair the dose history with whatever the protocol targets — pigmentation notes, response ratings, or general wellbeing tracking.

The mechanism of Melanotan-2 is characterized by its action as a non-selective agonist for a range of melanocortin receptors (MCRs). The melanocortin system is comprised of five distinct G-protein coupled receptors, labeled MC1R through MC5R, which are distributed differently throughout the body and mediate different physiological processes. While native α-MSH also interacts with several of these receptors, Melanotan-2 binds with high affinity to MC1R, MC3R, MC4R, and MC5R. This lack of selectivity is a defining feature and is responsible for the broad spectrum of effects observed in research and documented in personal-tracking logs.

The multi-receptor binding profile of Melanotan-2 is what distinguishes it from other melanocortin peptides like Melanotan-1 and bremelanotide (PT-141). MC1R is most famously studied for its role in regulating skin pigmentation and inflammation. MC3R and MC4R are heavily concentrated in the central nervous system and are subjects of intense study regarding their roles in energy homeostasis, appetite regulation, and sexual function. MC5R is studied for its function in regulating exocrine gland secretion. Because Melanotan-2 interacts with this entire suite of receptors, its observed response profile is more complex and wide-ranging than that of a more selective agonist.

Tracking Melanotan-2 unit counts

The phase transition from loading to maintenance is the easiest thing to lose track of without a structured log. Recording the date of the transition is what makes the timeline reconstructible later.

For this peptide, the most impactful data to track is the cumulative dose during the loading phase. The response curve is often closely tied not to any single administration but to the total amount of the peptide introduced over the entire initial period. An effective log should therefore calculate and display a running total of the cumulative milligrams administered from the start date. By correlating this cumulative figure with dated observations, a user can monitor the relationship between the total exposure and the observed outcome, which is a core purpose of systematic personal tracking.

In addition to quantitative data like dose and volume, a comprehensive log for Melanotan-2 should include fields for qualitative, subjective observations. Research links certain melanocortin receptors (MC3R, MC4R) to phenomena such as appetite modulation, transient facial flushing, and nausea. Scheduling and documenting the timing and intensity of such observations alongside the dosage data provides a richer dataset. This allows the user to later analyze potential correlations between dose timing, cumulative dose, and the presence or absence of these subjectively observed responses, creating a more complete personal record.

Common Melanotan-2 conversion mistakes

Continuing a loading-phase dose into what should have been the maintenance phase because no transition was recorded.
Reading 0.5 mg as 10 units regardless of vial concentration. The unit count depends on diluent volume.
Reusing the previous vial's unit count after changing diluent volume.
Letting reconstituted Melanotan-2 warm to room temperature on travel days.
Not writing the reconstitution date on the vial.
Assuming a linear response to each individual dose rather than scheduling and tracking the cumulative dose over a defined loading phase.
Failing to document an adjusted, higher-volume reconstitution plan, leading to significant errors in dose calculation when converting from units to milligrams.
Interpreting observed responses through the lens of a single-receptor mechanism instead of accounting for the established multi-receptor binding profile of Melanotan-2.

Frequently asked questions about Melanotan-2 mg ↔ units

How is Melanotan-2 reconstituted?

Add a measured volume of bacteriostatic water through the rubber stopper and swirl gently until the powder fully dissolves. A 10 mg vial with 2 mL of BAC water gives a concentration of 5 mg per mL.

How many units of Melanotan-2 are in 0.5 mg?

On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 0.5 mg is exactly 10 units on a U-100 syringe. With 4 mL of diluent, the same dose is 20 units.

Is Melanotan-2 dosed in loading and maintenance phases?

Many personal protocols use a daily loading phase followed by a less-frequent maintenance phase. Recording the date of the phase transition is what makes the timeline auditable later.

How long does a 10 mg Melanotan-2 vial last?

At a 0.5 mg daily dose, a 10 mg vial provides 20 doses — about 2.9 weeks of daily supply.

Does Melanotan-2 need to be refrigerated?

Lyophilized powder is typically stored refrigerated, and the reconstituted vial is kept refrigerated and used within several weeks.

How is Melanotan-2 different from Melanotan-1?

Both are synthetic alpha-MSH analogs. Melanotan-1 is closer in structure to native alpha-MSH and acts more selectively; Melanotan-2 is a shorter, more potent analog that binds multiple melanocortin receptors.

How does Melanotan-2 differ structurally and functionally from Melanotan-1?

The primary structural difference is that Melanotan-2 is a cyclic peptide, while Melanotan-1 is linear. This cyclization gives Melanotan-2 enhanced stability and a longer biological half-life. Functionally, this leads to a key difference in receptor selectivity; Melanotan-1 is highly selective for the MC1 receptor, whereas Melanotan-2 is a non-selective agonist that binds strongly to MC1R, MC3R, MC4R, and MC5R. This broader receptor engagement is why the two peptides are studied for different purposes and why tracking logs often document very different observational profiles.

What is the relationship between Melanotan-2 and PT-141 (bremelanotide)?

PT-141, also known as bremelanotide, is an active metabolite of Melanotan-2. It is a smaller peptide fragment corresponding to the core sequence of Melanotan-2 but lacks the specific amino acid residues that confer high affinity for the MC1 receptor. As a result, PT-141 is a more selective agonist, primarily targeting the MC3 and MC4 receptors. This difference in receptor targeting is why PT-141 is studied for effects related to sexual function and appetite, largely separate from the pigmentation effects associated with MC1R activation.

Why is documenting a 'loading phase' versus a 'maintenance phase' so important for tracking?

Documenting these two phases separately is critical for accurate data analysis. The loading phase is the initial period of dose accumulation where the goal is to reach a state of receptor saturation that produces a consistent, observable response. Tracking this phase allows a user to calculate the *total cumulative dose* required to reach their desired endpoint. The maintenance phase is a subsequent period of less frequent administration designed to sustain that state. Separating the two in a log creates an auditable record that clarifies the dose-response relationship.

Related on Peptide Pilot

Save your Melanotan-2 vial in the app

Download on the App Store